Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. - Wikidata - awgldk - TriplyDB

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

http://www.wikidata.org/entity/Q35161070

about

A critical role for the Sp1-binding sites in the transforming growth factor-beta-mediated inhibition of lipoprotein lipase gene expression in macrophages CD40 in coronary artery disease: a matter of macrophages?The role of platelets in the recruitment of leukocytes during vascular disease CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury.Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis.Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets.Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics.CD40L and Its Receptors in Atherothrombosis-An Update Inflammatory micro-environmental cues of human atherothrombotic arteries confer to vascular smooth muscle cells the capacity to trigger lymphoid neogenesis.Beta3 integrin deficiency promotes atherosclerosis and pulmonary inflammation in high-fat-fed, hyperlipidemic mice.Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice.Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation.Inflammation in coronary artery disease: potential role for immunomodulatory therapy.Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling.Novel Therapy for Atherosclerosis Using Recombinant Immunotoxin Against Folate Receptor β-Expressing Macrophages Future innovations in anti-platelet therapies.Autoimmunity in atherosclerosis: a protective response losing control?Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis.Abrogated transforming growth factor beta receptor II (TGFβRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis.TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases.The Role of Immunogenicity in Cardiovascular Disease.Tumor necrosis factor superfamily molecules in acute coronary syndromes.The CD40-CD40L system in cardiovascular disease.Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets.Therapeutic strategies to deplete macrophages in atherosclerotic plaques.Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis.CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications.Inflammation and immune system interactions in atherosclerosis.CD154: the atherosclerotic risk factor in rheumatoid arthritis?Regulation of atherosclerotic plaque inflammation.Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis.Effect of Smoking on Metalloproteinases (MMPs) Activity in Patients with Acute Myocardial Infarction (AMI).ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis.Blockade of CD40-TRAF2,3 or CD40-TRAF6 is sufficient to inhibit pro-inflammatory responses in non-haematopoietic cells.Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation.Antiplatelet therapy: current strategies and future trends.T-cell co-stimulators as anti-inflammatory targets for atherosclerotic disease.

P2860

Q24795518-14DF4F5F-2A2D-480E-8297-86ACA3655DE6 Q26752784-83DEF7FA-AE53-4B94-B620-AE6269F36A8D Q26801407-730C10D9-17D7-4802-84EC-791482D3AFC9 Q30441065-B07F2FF5-E262-42A2-AD5B-16F181EC7828 Q30497499-15BACC1E-578C-48F9-8A18-4ABBBC03D37E Q33183129-8E865978-1F83-444E-BB10-3FE119C53586 Q33656103-CC2D51F9-384E-44F6-AA9E-171848AB8691 Q33805176-3DDB5F7F-CECF-4CDE-932E-AFA228F0C449 Q33814059-DA0CC962-F8E7-4BDB-8448-877D8E61DD0D Q34790656-DDA96FF2-14E0-47CD-B090-C4EEB826C41B Q35144122-8C6495B0-3382-44F3-B01E-FDD409A851E8 Q35789286-AD36907D-BA6D-4AB0-8AC5-E978E2CB899D Q35824531-A9E5AF39-5259-482C-B35F-28D67C15E964 Q36216095-18A7EF41-0009-4E2B-BD18-8DAA055DFFD7 Q36283698-199A2FFC-970C-4AD8-A76B-84D10399BC84 Q36314881-72938EFD-7E56-45A8-A2A0-4B29236924C6 Q36350146-D0697FF7-690B-44BF-9D36-D796A18FC6EB Q36366225-8A7C200F-A735-4706-A0A7-F419BBD2114E Q36753593-98DF06F5-F522-44F6-BCA3-A00C9B01BFBB Q37138017-3223F2A7-F9F9-4892-902E-0403161B1923 Q37300823-281FE52A-6DB0-4BC8-AA8D-CD0819D2F7DA Q37407750-687B20D9-EBCC-4D23-B57B-CAA277DEDD20 Q37494039-F531FDEE-6E9C-4337-B9EC-B07766EE6D06 Q37560012-FEE48626-FA15-4494-B8E8-FCE33E088672 Q37805514-68E63C9D-8656-42B6-8ED6-9C99F39366DE Q37829738-FFC116C5-0074-49F9-96AA-A7F2D01B80F9 Q37866627-643AE374-BF11-468F-8F08-945A813AC2AF Q37981725-63F14631-B718-401E-B124-4915D04EB91E Q38016490-69E7BD0A-B769-4215-B212-E83ADB2F6C8F Q38042321-3763D986-9310-464B-A2E1-607B3E849664 Q38083555-050D3332-8370-4E1F-BF25-EB2B9D974CAC Q38083874-1A2876F5-D205-42EF-B71E-129BAFE4E41B Q38396097-EC9635B0-B2D9-43A3-AFB5-E02D0A251C74 Q38406177-B832D932-9231-4740-AAE2-FC50E1E8D210 Q38587974-C638B368-7BB6-471A-84A5-5C2DD4F8E394 Q38737500-539A02ED-CBEE-4108-A447-09835C24755A Q38972708-E848799A-6718-4A32-8977-6EBB2E62ECB3 Q39454807-4AB3CB10-9FB3-4EB8-9C8F-AC329E7B5DB5 Q40329892-C3DB3085-1F76-41C2-A69A-EA046903FFC3 Q40347857-A5D00B52-501B-43C7-8C2F-4918C88BF81C

P2860

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

http://www.wikidata.org/entity/Q35161070

description

2000 nî lūn-bûn

@nan

2000 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

name

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

@ast

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

@en

type

label

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

@ast

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

@en

prefLabel

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

@ast

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

@en

P1433

Q35161070-1F3B9B16-1B87-44F1-B1CD-53C24547564F

P1476

Q35161070-61CAFF43-4502-42F1-84DB-EA044589403C

P2093

Q35161070-1F4B255C-9C7D-49C1-9566-750D93F4EA9A

Q35161070-51C17269-5C46-4B30-B05A-5F25D08C0C65

Q35161070-64DF4365-DEC1-4FE2-A610-C4E4D7E1D1D9

Q35161070-7AF0D681-9D1E-4921-84C0-72A8B5183B1F

Q35161070-7DB9FAA4-5490-4E02-8E74-E400A5E76AF3

Q35161070-8B696CDA-BBD7-4564-A221-20AB32067D9E

P2860

Q35161070-01FCA46E-AD87-413B-9B1C-E05E5E1F21A1

Q35161070-06A69D57-6D98-45AD-B067-D87D03C18A82

Q35161070-121DEA44-154C-4A71-91FF-F3B21C34E2FC

Q35161070-12D75A7E-D298-4C40-8F7F-BCD85327A574

Q35161070-13DA81A0-B15C-47B0-B63F-8ADCE4CF6B1A

Q35161070-1F1E8764-CE05-4319-9E78-B365240B75C6

Q35161070-1F865A8A-5046-45AC-9881-D989BFD65764

Q35161070-23E82497-1219-4E2A-ADD6-2C15FD657C2F

Q35161070-25970ED5-85F3-4032-B61B-540741E28517

Q35161070-278ED654-B408-4F48-99E9-6982467D6656

P304

Q35161070-60A5087F-B29F-4BA4-816E-BF2D88C53AA7

P31

Q35161070-FC0F2A45-A87A-44F7-BDD0-2AF7BACDB59D

P356

Q35161070-78B8D4E4-E6DB-4DDF-BC26-F3C16D4F673D

P407

Q35161070-6054BD9F-D365-4ADC-A838-1E87D2A69D20

P433

Q35161070-8D7B6D86-CA4A-434E-A49F-720F77A44271

P478

Q35161070-3DE22A1D-67CA-4592-BFB6-DCBFBB4C6945

P577

Q35161070-23415D31-0AB9-4BC1-B78E-554F970E30A9

P5875

Q35161070-71B5E04E-BDEE-463A-B271-E743F699552F

P698

Q35161070-18822274-BF85-455C-BDC2-CD05B20F6CD4

P921

Q35161070-5C8931B0-18C2-4CB5-831C-465F75056D11

P932

Q35161070-4EDEA6B2-FE6B-4D2A-81D9-BB41B32A1E44

P356

PNAS.97.13.7464

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

@en

P2093

Burkly LC

http://www.w3.org/2001/XMLSchema#string

Cleutjens KB

http://www.w3.org/2001/XMLSchema#string

Daemen MJ

http://www.w3.org/2001/XMLSchema#string

Heeneman S

http://www.w3.org/2001/XMLSchema#string

Koteliansky VE

http://www.w3.org/2001/XMLSchema#string

Lutgens E

http://www.w3.org/2001/XMLSchema#string

P2860

CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice

Reduction of atherosclerosis in mice by inhibition of CD40 signalling

Atherosclerosis — An Inflammatory Disease

Transforming growth factor beta in tissue fibrosis

Regulation of the thrombotic potential of atheroma.

CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40.

Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice.

CD40 ligation induces tissue factor expression in human vascular smooth muscle cells.

Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis.

P304

7464-7469

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.97.13.7464

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2000-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24448202

http://www.w3.org/2001/XMLSchema#string

P698

10861013

http://www.w3.org/2001/XMLSchema#string

P921

P932

16568

http://www.w3.org/2001/XMLSchema#string